ClinicalTrials.gg
CompletedNCT00885755Updated Mar 29, 2018Results posted

A Study of Herceptin (Trastuzumab)and Biomarkers in Patients With HER2-Positive Metastatic Breast Cancer

A Phase 2 interventional study of Standard taxane therapy and capecitabine [Xeloda] in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 13 sites in 4 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-03-29.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 233 studies testing capecitabine in Breast Neoplasms — 32 open to participants now, 41 under way, 10 of them phase 3. Capecitabine · Breast Neoplasms.

Enrollment
161st of 227
33 · median 54
Started
2009
with 11 others
Phase 2
121 of 233
20 open now
Registered
104th of 233
by date
Lead sponsor
12 of 233
Hoffmann-La Roche

Among the 233 studies testing capecitabine in Breast Neoplasms, this one is the 161st largest by enrollment of the 227 interventional ones that give a count, is one of 12 that started in 2009, is one of 121 in phase 2, and was the 104th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

32 of the 233 studies testing capecitabine in Breast Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

27 more — sign in →

By country, each count listing its studies:

All 32 open studies →

About capecitabine

Capecitabine: first FDA approval 1998 (XELODA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 233 studies testing capecitabine in Breast Neoplasms, or all of them as a file.
02

Study summary

This single arm study will evaluate alterations in molecular marker expression in HER2-positive targeted therapy, and will evaluate the effect of continued treatment with Herceptin and Xeloda beyond progression following initial Herceptin-taxane chemotherapy. Patients who develop progressive disease will receive first-line Herceptin (8mg/kg iv loading dose and 6mg/kg iv every 3 weeks) + taxane therapy. patients who develop progressive disease within 9 weeks of treatment will continue treatment with Herceptin in combination with Xeloda (1000mg/m2 po bid on days 1-14 of each 3-week cycle).Biopsies of tumor tissue will be taken for biomarker and gene profiling evaluation. The anticipated time on study treatment is until disease progression, intolerable side effects or patient choice, and the target sample size is 100 individuals.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • female patients, >=18 years of age;
  • -positive breast cancer;
  • al least one site amenable for core ;
  • >50%.

Exclusion criteria

Exclusion Criteria:

  • prior adjuvant/ Herceptin within past 6 months;
  • prior adjuvant taxane therapy within past 12 months;
  • use of chemotherapy, immunotherapy or biological anticancer therapy within past 3 weeks;
  • known bleeding diatheses.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    1

    Drug: Standard taxane therapy · Drug: capecitabine [Xeloda] · Drug: trastuzumab [Herceptin]

Interventions

  • DrugStandard taxane therapy

    As prescribed

  • 1000mg/m2 po bid on days 1-14 of each 3-week cycle (only in patients who have progressed)

  • 8mg/kg iv loading dose on day 1 of first 3-week cycle, and 6mg/kg iv on day 1 of each subsequent cycle

06

What researchers measure

Primary outcomes

  1. Part I: Progression Free Survival (PFS) by Biomarker

    Progression was defined as an increase by at least 20 percent (%) from the smallest value in the Sum of Longest Diameter (SLD) of lesions. Biomarkers investigated: p95 human epidermal growth factor receptor 2 (p95HER2) positive (+ve) and negative (-ve) , insulin growth factor-1 receptor (IGF1R) less than (\<) median and greater than or equal to (≥) median membrane H score, c-MET \<median and ≥median membrane H score, phosphatase and tensin homolog gene (PTEN) \<median and ≥median cytoplasm H score, HER2 \<median and ≥median membrane H score, phosphatidylinositol-3-kinase (PI3K) catalytic subunit wild type (WT) and mutation (M), and FC gamma receptors IIIa homozygous Phenyl alanine (FF), heterozygous Phenyl alanine/Valine (VF) and homozygous Valine (VV), receptor IIa Phenotypes homozygous Histidine (HH), heterozygous Histidine/Arginine (HR) and homozygous Arginine (RR) IIb phenotypes homozygous Isoleucien (II),heterozygous Isoleucine/Threonine (IT) and homozygous Threonine (TT) .

    Time frame: End of first 2 Cycles (Weeks 3 and 6), every 3 Cycles for 18 weeks, then every 4 cycles until progression, unacceptable toxicity or participant decision to cease treatment up to 46 months

  2. Part II: Progression Free Survival (PFS) by Biomarker

    PFS was calculated from first study medication in Part II to date of progression or death.The relationship between PFS and the following biomarker variables was investigated in each of study Part 1 and 2: p95HER2 +ve and -ve population, IGF1R \<median and ≥ median membrane H score, c-MET \<median and ≥median membrane H score, PTEN \<median and ≥median cytoplasm H score, HER2 \<median and ≥median membrane H score, PI3K catalytic subunit WT and M, and FC gamma receptors IIIa, IIa and IIb Phenotypes FF, VF and VV, HH, HR and RR, and II, IT and TT.

    Time frame: End of first 2 Cycles (Weeks 3 and 6), every 3 cycles for 18 weeks, then every 4 cycles until progression, unacceptable toxicity or participant decision to cease treatment up to 46 months

  3. Part I: Time to Progression (TTP) by Biomarker

    Progression was defined as an increase by at least 20% from the smallest value in the SLD of lesions.TTP was determined as the time in months from the date of screening until first progression.The relationship between PFS and the following biomarker variables was investigated in each of study Part 1 and 2: p95 HER2 +ve and -ve population, IGF1R \<median and ≥median, c-MET \<median and ≥median, PTEN \<median and ≥median, HER2 \<median and ≥median, PI3K catalytic subunit WT and M, and FC gamma receptors IIIa, IIa and IIb Phenotypes FF, VF and VV, HH, HR and RR, and II, IT and TT . The correlation between the biomarker variables and TTP were investigated using a univariate Cox regression model and time-to-event methods (Kaplan-Meier).

    Time frame: End of first 2 Cycles (Weeks 3 and 6), every 3 Cycles for 18 weeks, then every 4 cycles until progression, unacceptable toxicity or participant decision to cease treatment up to 46 weeks

  4. Part II: TTP by Biomarker

    TTP was calculated from first study medication in Part II to date of progression. The relationship between TTP and the following biomarker variables was investigated in each of study Part 1 and 2: p95 HER2 +ve and -ve population, IGF1R \<median and ≥median, c-MET \<median and ≥median, PTEN \<median and ≥median, HER2 \<median and ≥median, PI3K catalytic subunit WT and M, and FC gamma receptors IIIa, IIa and IIb Phenotypes FF, VF and VV, HH, HR and RR, and II, IT and TT .

    Time frame: End of first 2 Cycles (Weeks 3 and 6), every 3 cycles for 18 weeks, then every 4 cycles until progression, unacceptable toxicity or participant decision to cease treatment up to 46 months

  5. Part I: Percentage of Participants With a Best Overall Response (BOR) of Complete Response (CR), Partial Response (PR), Stable Disease (SD) or Progrerssive Disease (PD) by Biomarker

    BOR was defined according to the Response Evaluation Criteria In Solid Tumors (RECIST). CR: disappearance of all target lesions and all pathological lymph nodes below 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD: At least a 20% increase in the sum of diameters of target lesions, and the sum must also demonstrate an absolute increase of at least 5 mm or persistence of non-target lesions. The relationship between best response and the following biomarkers was investigated: p95 HER2 (+ve/-ve), IGF1R, c-MET, PTEN, HER2 (median/≥median), PI3K catalytic subunit (WT/M), and FC gamma receptors IIIa, IIa and IIb (phenotypes FF, VF, VV, HH, HR, RR and II, IT and TT respectively). The correlation between the biomarker variables and percentage of participants with best response were investigated using a univariate regression analysis.

    Time frame: End of first 2 Cycles (Weeks 3 and 6), every 3 cycles for 18 weeks, then every 4 cycles until progression, unacceptable toxicity or participant decision to cease treatment up to 46 weeks

  6. Part II: Percentage of Participants With a Best Overall Response of CR, PR, SD or PD by Biomarker

    Best Overall response was defined according to RECIST. CR: disappearance of all target lesions and all pathological lymph nodes below 10 mm.PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD: At least a 20% increase in the sum of diameters of target lesions, and the sum must also demonstrate an absolute increase of at least 5 mm or persistence of non-target lesions. The relationship between best response and the following biomarkers was investigated: p95 HER2 (+ve/-ve), IGF1R, c-MET, PTEN, HER2 (\<median/≥median) , PI3K catalytic subunit (WT/M), and FC gamma receptors IIIa, IIa and IIb (phenotypes FF, VF, VV, HH, HR, RR and II, IT and TT respectively). The correlation between the biomarker variables and percentage of participants with best response were investigated using a univariate regression analysis.

    Time frame: End of first 2 Cycles (Weeks 3 and 6), every 3 cycles for 18 weeks, then every 4 cycles until progression, unacceptable toxicity or participant decision to cease treatment up to 46 months

Secondary outcomes

  1. Part I: TTP in Intent to Treat (ITT) Population

    TTP was determined as the time in months from the date of screening until first progression. In participants with measurable disease, progression was defined according to RECIST (SLD increased by at least 20% from the smallest value on study \[including baseline, if that is the smallest\]). In participants with non-measurable disease, progression was defined as the presence of new lesions or unequivocal progression during treatment.

    Time frame: End of first 2 Cycles (Weeks 3 and 6), every 3 cycles for 18 weeks, then every 4 cycles until progression, unacceptable toxicity or participant decision to cease treatment up to 46 months

  2. Part I: PFS in ITT Population

    PFS was determined as the time in months from the date of screening until first progression. In participants with measurable disease, progression was defined according to RECIST (SLD increased by at least 20% from the smallest value on study \[including baseline, if that is the smallest\]).. In participants with non-measurable disease, progression was defined as the presence of new lesions or unequivocal progression during treatment.

    Time frame: End of first 2 Cycles (Weeks 3 and 6), every 3 cycles for 18 weeks, then every 4 cycles until progression, unacceptable toxicity or participant decision to cease treatment up to 46 months

  3. Part II: TTP in Intent to Treat (ITT) Population

    TTP was calculated from first study medication in Part II to date of progression. In participants with measurable disease progression was defined according to RECIST(SLD increased by at least 20% from the smallest value on study \[including baseline, if that is the smallest\]). In participants with non-measurable disease, progression was defined as the presence of new lesions or unequivocal progression during treatment.

    Time frame: End of first 2 Cycles (Weeks 3 and 6), every 3 Cycles for 18 weeks, then every 4 cycles until progression, unacceptable toxicity or participant decision to cease treatment up to 46 months

  4. Part II: PFS in ITT Population

    PFS was calculated from first study medication in Part II to date of progression or death. In participants with measurable disease progression was defined according to RECIST (SLD increased by at least 20% from the smallest value on study \[including baseline, if that is the smallest\]). In participants with non-measurable disease, progression was defined as the presence of new lesions or unequivocal progression during treatment.

    Time frame: End of first 2 Cycles (Weeks 3 and 6), every 3 cycles for 18 weeks, then every 4 cycles until progression, unacceptable toxicity or participant decision to cease treatment up to 46 months

  5. Overall Survival in Per Protocol Population

    Overall survival was calculated in months from the day of screening until death.

    Time frame: End of first 2 Cycles (Weeks 3 and 6), every 3 cycles for 18 weeks, then every 4 cycles until death (up to 46 months)

  6. Overall Survival in ITT Population

    Overall survival was calculated in months from the day of screening until death.

    Time frame: End of first 2 Cycles (Weeks 3 and 6), every 3 cycles for 18 weeks, then every 4 cycles until death (up to 46 months)

  7. Part I and II: Percentage of Participants With a Best Overall Response of CR or PR in ITT Population

    Best Overall response was defined according to RECIST. CR: disappearance of all target lesions and all pathological lymph nodes below 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD: At least a 20% increase in the sum of diameters of target lesions, and the sum must also demonstrate an absolute increase of at least 5 mm or persistence of non-target lesions.

    Time frame: End of first 2 Cycles (Weeks 3 and 6), every 3 Cycles for 18 weeks, then every 4 cycles until progression, unacceptable toxicity or participant decision to cease treatment up to 46 months

  8. Part I and II: Percentage of Participants With a Response by Best Overall Response by CR, PR, SD or PD in ITT Population

    Best Overall response was defined according to RECIST. CR: disappearance of all target lesions and all pathological lymph nodes below 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD: At least a 20% increase in the sum of diameters of target lesions, and the sum must also demonstrate an absolute increase of at least 5 mm or persistence of non-target lesions.

    Time frame: End of first 2 Cycles (Weeks 3 and 6), every 3 cycles for 18 weeks, then every 4 cycles until progression, unacceptable toxicity or participant decision to cease treatment up to 46 months

07

Results

Posted Oct 5, 2015
Limitations and caveats
The study was prematurely terminated on December 31, 2012. The end of study follow-up was February 18, 2013.

Participant flow

Part I: Trastuzumab+Taxane
Participant flow — Part I: Trastuzumab+Taxane
MilestoneGroup A:Trastuzumab+Taxane /Capecitabine (6 Weeks)Group B: Trastuzumab+Taxane/ Capecitabine <6 WeeksNo Group
Started3111
Completed1310
Not completed1801
Withdrew: Adverse event100
Withdrew: Unknown reason1600
Withdrew: Sufficient response achieved100
Withdrew: Death001
Part II: Trastuzumab + Capecitabine.
Participant flow — Part II: Trastuzumab + Capecitabine.
MilestoneGroup A:Trastuzumab+Taxane /Capecitabine (6 Weeks)Group B: Trastuzumab+Taxane/ Capecitabine <6 WeeksNo Group
Started1310
Completed810
Not completed500
Withdrew: Unknown reason500

Outcome measures

PrimaryPart I: Progression Free Survival (PFS) by Biomarker

Progression was defined as an increase by at least 20 percent (%) from the smallest value in the Sum of Longest Diameter (SLD) of lesions. Biomarkers investigated: p95 human epidermal growth factor receptor 2 (p95HER2) positive (+ve) and negative (-ve) , insulin growth factor-1 receptor (IGF1R) less than (\<) median and greater than or equal to (≥) median membrane H score, c-MET \<median and ≥median membrane H score, phosphatase and tensin homolog gene (PTEN) \<median and ≥median cytoplasm H score, HER2 \<median and ≥median membrane H score, phosphatidylinositol-3-kinase (PI3K) catalytic subunit wild type (WT) and mutation (M), and FC gamma receptors IIIa homozygous Phenyl alanine (FF), heterozygous Phenyl alanine/Valine (VF) and homozygous Valine (VV), receptor IIa Phenotypes homozygous Histidine (HH), heterozygous Histidine/Arginine (HR) and homozygous Arginine (RR) IIb phenotypes homozygous Isoleucien (II),heterozygous Isoleucine/Threonine (IT) and homozygous Threonine (TT) .

Time frame:
End of first 2 Cycles (Weeks 3 and 6), every 3 Cycles for 18 weeks, then every 4 cycles until progression, unacceptable toxicity or participant decision to cease treatment up to 46 months
Reported as:
Median · months
Part I: Progression Free Survival (PFS) by Biomarker
monthsGroup A: Trastuzumab+Taxane /Capecitabine (6 Weeks)Group B: Trastuzumab+Taxane/ Capecitabine <6 Weeks
p95 HER2 +ve (n=9,0)NA (3.384 to NA)NA (NA to NA)
p95 HER2 -ve (n=15,1)13.963 (7.261 to 22.407)1.216 (NA to NA)
IGF1R <median (n=12,0)12.649 (4.698 to NA)NA (NA to NA)
IGF1R ≥median (n=14,1)22.209 (7.261 to NA)1.216 (NA to NA)
c-MET <median (n=10,1)18.595 (3.384 to NA)1.216 (NA to NA)
c-MET ≥median (n=15,0)13.733 (7.031 to NA)NA (NA to NA)
PTEN <median (n=12,0)22.209 (5.914 to NA)NA (NA to NA)
PTEN ≥median (n=14,1)13.963 (6.374 to 31.179)1.216 (NA to NA)
HER2 <median (n=11,1)13.733 (3.384 to NA)1.216 (NA to NA)
HER2 ≥median (n=14,0)22.209 (7.031 to NA)NA (NA to NA)
PI3K Amino Acids WT (n=17,1)13.848 (7.261 to NA)1.216 (NA to NA)
PI3K Amino Acids M (n=9,0)22.407 (4.698 to NA)NA (NA to NA)
FC Gamma Receptor IIIa F176V FF (n=9,0)10.612 (3.384 to NA)NA (NA to NA)
FC Gamma Receptor IIIa F176V VF (n=5,1)11.335 (9.528 to NA)1.216 (NA to NA)
FC Gamma Receptor IIIa F176V VV (n=4,0)22.407 (22.209 to NA)NA (NA to NA)
FC Gamma Receptor IIa R166H HH (n=3,0)NA (9.528 to NA)NA (NA to NA)
FC Gamma Receptor IIa R166H HR (n=8,1)22.209 (3.384 to NA)1.216 (NA to NA)
FC Gamma Receptor IIa R166H RR (n=8,0)13.963 (5.914 to NA)NA (NA to NA)
FC Gamma Receptor IIb I232T II (n=12,1)11.335 (5.914 to NA)1.216 (NA to NA)
FC Gamma Receptor IIb I232T IT (n=1,0)NA (NA to NA)NA (NA to NA)
FC Gamma Receptor IIb I232T TT (n=1,0)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Group A: Trastuzumab+Taxane /Capecitabine (6 Weeks) · Hazard ratio (hr): 0.41 · 95% CI 0.109 to 1.535
  • Group A: Trastuzumab+Taxane /Capecitabine (6 Weeks) · Hazard ratio (hr): 1.19 · 95% CI 0.430 to 3.282
  • Group A: Trastuzumab+Taxane /Capecitabine (6 Weeks) · Hazard ratio (hr): 0.86 · 95% CI 0.306 to 2.425
  • Group A: Trastuzumab+Taxane /Capecitabine (6 Weeks) · Hazard ratio (hr): 0.49 · 95% CI 0.164 to 1.453
  • Group A: Trastuzumab+Taxane /Capecitabine (6 Weeks) · Hazard ratio (hr): 1.09 · 95% CI 0.377 to 3.160
  • Group A: Trastuzumab+Taxane /Capecitabine (6 Weeks) · Hazard ratio (hr): 1.30 · 95% CI 0.409 to 4.132
  • Group A: Trastuzumab+Taxane /Capecitabine (6 Weeks) · Hazard ratio (hr): 1.183 · 95% CI 0.226 to 6.197
  • Group A: Trastuzumab+Taxane /Capecitabine (6 Weeks) · Hazard ratio (hr): 1.989 · 95% CI 0.378 to 10.470
  • Group A: Trastuzumab+Taxane /Capecitabine (6 Weeks) · Hazard ratio (hr): 1.732 · 95% CI 0.235 to 12.783
  • Group A: Trastuzumab+Taxane /Capecitabine (6 Weeks) · Hazard ratio (hr): 0.576 · 95% CI 0.067 to 4.968
  • Group A: Trastuzumab+Taxane /Capecitabine (6 Weeks) · Hazard ratio (hr): 0.743 · 95% CI 0.082 to 6.720
  • Group A: Trastuzumab+Taxane /Capecitabine (6 Weeks) · Hazard ratio (hr): 1.073 · 95% CI 0.274 to 4.199
SecondaryPart I: TTP in Intent to Treat (ITT) Population

TTP was determined as the time in months from the date of screening until first progression. In participants with measurable disease, progression was defined according to RECIST (SLD increased by at least 20% from the smallest value on study \[including baseline, if that is the smallest\]). In participants with non-measurable disease, progression was defined as the presence of new lesions or unequivocal progression during treatment.

Time frame:
End of first 2 Cycles (Weeks 3 and 6), every 3 cycles for 18 weeks, then every 4 cycles until progression, unacceptable toxicity or participant decision to cease treatment up to 46 months
Reported as:
Median · months
Part I: TTP in Intent to Treat (ITT) Population
monthsGroup A: Trastuzumab+Taxane /Capecitabine (6 Weeks)Group B: Trastuzumab+Taxane/ Capecitabine <6 Weeks
Part I: TTP in Intent to Treat (ITT) Population22.21 (9.53 to NA)1.22 (NA to NA)
PrimaryPart II: Progression Free Survival (PFS) by Biomarker

PFS was calculated from first study medication in Part II to date of progression or death.The relationship between PFS and the following biomarker variables was investigated in each of study Part 1 and 2: p95HER2 +ve and -ve population, IGF1R \<median and ≥ median membrane H score, c-MET \<median and ≥median membrane H score, PTEN \<median and ≥median cytoplasm H score, HER2 \<median and ≥median membrane H score, PI3K catalytic subunit WT and M, and FC gamma receptors IIIa, IIa and IIb Phenotypes FF, VF and VV, HH, HR and RR, and II, IT and TT.

Time frame:
End of first 2 Cycles (Weeks 3 and 6), every 3 cycles for 18 weeks, then every 4 cycles until progression, unacceptable toxicity or participant decision to cease treatment up to 46 months
Reported as:
Median · months
Part II: Progression Free Survival (PFS) by Biomarker
monthsGroup A: Trastuzumab+Taxane /Capecitabine (6 Weeks)Group B: Trastuzumab+Taxane/ Capecitabine <6 Weeks
p95 +ve (n=2,0)8.148 (NA to NA)NA (NA to NA)
p95 -ve (n=5,1)3.450 (0.854 to 8.115)13.832 (NA to NA)
IGF1R <median (n=4,0)8.115 (0.854 to 8.115)NA (NA to NA)
IGF1R ≥median (n=4,1)4.074 (1.971 to 8.148)13.832 (NA to NA)
c-MET<median (n=3,1)4.698 (3.450 to 4.698)13.832 (NA to NA)
c-MET≥median (n=4,0)5.043 (0.854 to 8.148)NA (NA to NA)
PTEN <median (n=4,0)4.698 (1.971 to 8.115)NA (NA to NA)
PTEN ≥median (n=3,1)3.450 (0.854 to 8.148)13.832 (NA to NA)
HER2 <median (n=2,1)8.148 (NA to NA)13.832 (NA to NA)
HER2 ≥median (n=5,0)3.450 (0.854 to 8.115)NA (NA to NA)
PI3K Amino Acids WT (n=10,1)5.651 (1.971 to 24.214)13.832 (NA to NA)
PI3K Amino Acids M (n=2,0)4.485 (0.854 to 8.115)NA (NA to NA)
FC Gamma Receptor IIIa F176V FF (n=4,0)4.320 (0.854 to 8.148)NA (NA to NA)
FC Gamma Receptor IIIa F176V VF (n=2,1)13.832 (3.450 to 24.214)13.832 (NA to NA)
FC Gamma Receptor IIIa F176V VV (n=2,0)NA (NA to NA)NA (NA to NA)
FC Gamma Receptor IIa R166H HH (n=1,0)3.450 (NA to NA)NA (NA to NA)
FC Gamma Receptor IIa R166H HR (n=5,1)8.115 (0.854 to 8.148)13.832 (NA to NA)
FC Gamma Receptor IIa R166H RR (n=3,0)5.651 (2.990 to 24.214)NA (NA to NA)
FC Gamma Receptor IIb I232T II (n=7,1)5.651 (0.854 to 24.214)13.832 (NA to NA)
PrimaryPart I: Time to Progression (TTP) by Biomarker

Progression was defined as an increase by at least 20% from the smallest value in the SLD of lesions.TTP was determined as the time in months from the date of screening until first progression.The relationship between PFS and the following biomarker variables was investigated in each of study Part 1 and 2: p95 HER2 +ve and -ve population, IGF1R \<median and ≥median, c-MET \<median and ≥median, PTEN \<median and ≥median, HER2 \<median and ≥median, PI3K catalytic subunit WT and M, and FC gamma receptors IIIa, IIa and IIb Phenotypes FF, VF and VV, HH, HR and RR, and II, IT and TT . The correlation between the biomarker variables and TTP were investigated using a univariate Cox regression model and time-to-event methods (Kaplan-Meier).

Time frame:
End of first 2 Cycles (Weeks 3 and 6), every 3 Cycles for 18 weeks, then every 4 cycles until progression, unacceptable toxicity or participant decision to cease treatment up to 46 weeks
Reported as:
Median · months
Part I: Time to Progression (TTP) by Biomarker
monthsGroup A: Trastuzumab+Taxane /Capecitabine (6 Weeks)Group B: Trastuzumab+Taxane/ Capecitabine <6 Weeks
p95 +ve (n=9,0)NA (3.384 to NA)NA (NA to NA)
p95 -ve (n=15,1)13.963 (7.261 to 22.407)1.216 (NA to NA)
IGF1R <median (n=12,0)11.335 (4.698 to NA)NA (NA to NA)
IGF1R ≥median (n=14,1)22.407 (5.914 to NA)1.216 (NA to NA)
c-MET <median (n=10,1)31.179 (3.384 to NA)1.216 (NA to NA)
c-MET ≥median (n=15,0)22.209 (6.374 to NA)NA (NA to NA)
PTEN <median (n=12,0)22.209 (5.914 to NA)NA (NA to NA)
PTEN ≥median (n=14,1)13.963 (6.374 to 31.179)1.216 (NA to NA)
HER2 <median (n=11,1)NA (3.384 to NA)1.216 (NA to NA)
HER2 ≥median (n=14,0)22.209 (7.031 to NA)NA (NA to NA)
PI3K Amino Acids WT (n=17,1)13.963 (7.261 to NA)1.216 (NA to NA)
PI3K Amino Acids M (n=9,00)22.407 (4.698 to NA)NA (NA to NA)
FC Gamma Receptor IIIa F176V FF (n=9,0)13.963 (3.384 to NA)NA (NA to NA)
FC Gamma Receptor IIIa F176V VF (n=5,1)11.335 (9.528 to NA)1.216 (NA to NA)
FC Gamma Receptor IIIa F176V VV (n=4,0)22.407 (22.209 to NA)NA (NA to NA)
FC Gamma Receptor IIa R166H HH (n=3,0)NA (9.528 to NA)NA (NA to NA)
FC Gamma Receptor IIa R166H HR (n=8,1)22.209 (3.384 to NA)1.216 (NA to NA)
FC Gamma Receptor IIa R166H RR (n=8,0)13.963 (5.914 to NA)NA (NA to NA)
FC Gamma Receptor IIb I232T II (n=12,1)13.963 (5.914 to NA)1.216 (NA to NA)
FC Gamma Receptor IIb I232T IT (n=1,0)NA (NA to NA)NA (NA to NA)
FC Gamma Receptor IIb I232T TT (n=1,0)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Group A: Trastuzumab+Taxane /Capecitabine (6 Weeks) · Hazard ratio (hr): 0.46 · 95% CI 0.120 to 1.790
  • Group A: Trastuzumab+Taxane /Capecitabine (6 Weeks) · Hazard ratio (hr): 1.18 · 95% CI 0.394 to 3.518
  • Group A: Trastuzumab+Taxane /Capecitabine (6 Weeks) · Hazard ratio (hr): 0.82 · 95% CI 0.268 to 2.514
  • Group A: Trastuzumab+Taxane /Capecitabine (6 Weeks) · Hazard ratio (hr): 0.57 · 95% CI 0.183 to 1.768
  • Group A: Trastuzumab+Taxane /Capecitabine (6 Weeks) · Hazard ratio (hr): 0.81 · 95% CI 0.242 to 2.733
  • Group A: Trastuzumab+Taxane /Capecitabine (6 Weeks) · Hazard ratio (hr): 1.11 · 95% CI 0.337 to 3.632
  • Group A: Trastuzumab+Taxane /Capecitabine (6 Weeks) · Hazard ratio (hr): 0.957 · 95% CI 0.172 to 5.336
  • Group A: Trastuzumab+Taxane /Capecitabine (6 Weeks) · Hazard ratio (hr): 1.666 · 95% CI 0.298 to 9.305
  • Group A: Trastuzumab+Taxane /Capecitabine (6 Weeks) · Hazard ratio (hr): 1.732 · 95% CI 0.235 to 12.783
  • Group A: Trastuzumab+Taxane /Capecitabine (6 Weeks) · Hazard ratio (hr): 0.576 · 95% CI 0.067 to 4.968
  • Group A: Trastuzumab+Taxane /Capecitabine (6 Weeks) · Hazard ratio (hr): 0.956 · 95% CI 0.098 to 9.319
  • Group A: Trastuzumab+Taxane /Capecitabine (6 Weeks) · Hazard ratio (hr): 1.292 · 95% CI 0.296 to 5.640
SecondaryPart I: PFS in ITT Population

PFS was determined as the time in months from the date of screening until first progression. In participants with measurable disease, progression was defined according to RECIST (SLD increased by at least 20% from the smallest value on study \[including baseline, if that is the smallest\]).. In participants with non-measurable disease, progression was defined as the presence of new lesions or unequivocal progression during treatment.

Time frame:
End of first 2 Cycles (Weeks 3 and 6), every 3 cycles for 18 weeks, then every 4 cycles until progression, unacceptable toxicity or participant decision to cease treatment up to 46 months
Reported as:
Median · months
Part I: PFS in ITT Population
monthsGroup A: Trastuzumab+Taxane /Capecitabine (6 Weeks)Group B: Trastuzumab+Taxane/ Capecitabine <6 Weeks
Part I: PFS in ITT Population18.60 (8.08 to NA)1.22 (NA to NA)
SecondaryPart II: TTP in Intent to Treat (ITT) Population

TTP was calculated from first study medication in Part II to date of progression. In participants with measurable disease progression was defined according to RECIST(SLD increased by at least 20% from the smallest value on study \[including baseline, if that is the smallest\]). In participants with non-measurable disease, progression was defined as the presence of new lesions or unequivocal progression during treatment.

Time frame:
End of first 2 Cycles (Weeks 3 and 6), every 3 Cycles for 18 weeks, then every 4 cycles until progression, unacceptable toxicity or participant decision to cease treatment up to 46 months
Reported as:
Median · months
Part II: TTP in Intent to Treat (ITT) Population
monthsGroup A: Trastuzumab+Taxane /Capecitabine (6 Weeks)Group B: Trastuzumab+Taxane/ Capecitabine <6 Weeks
Part II: TTP in Intent to Treat (ITT) Population5.65 (2.99 to 8.15)13.83 (NA to NA)
SecondaryPart II: PFS in ITT Population

PFS was calculated from first study medication in Part II to date of progression or death. In participants with measurable disease progression was defined according to RECIST (SLD increased by at least 20% from the smallest value on study \[including baseline, if that is the smallest\]). In participants with non-measurable disease, progression was defined as the presence of new lesions or unequivocal progression during treatment.

Time frame:
End of first 2 Cycles (Weeks 3 and 6), every 3 cycles for 18 weeks, then every 4 cycles until progression, unacceptable toxicity or participant decision to cease treatment up to 46 months
Reported as:
Median · months
Part II: PFS in ITT Population
monthsGroup A: Trastuzumab+Taxane /Capecitabine (6 Weeks)Group B: Trastuzumab+Taxane/ Capecitabine <6 Weeks
Part II: PFS in ITT Population5.65 (2.99 to 24.21)13.83 (NA to NA)
SecondaryOverall Survival in Per Protocol Population

Overall survival was calculated in months from the day of screening until death.

Time frame:
End of first 2 Cycles (Weeks 3 and 6), every 3 cycles for 18 weeks, then every 4 cycles until death (up to 46 months)
Reported as:
Median · months
Overall Survival in Per Protocol Population
monthsGroup A: Trastuzumab+Taxane /Capecitabine (6 Weeks)
Overall Survival in Per Protocol Population36.40 (6.57 to 40.28)
SecondaryOverall Survival in ITT Population

Overall survival was calculated in months from the day of screening until death.

Time frame:
End of first 2 Cycles (Weeks 3 and 6), every 3 cycles for 18 weeks, then every 4 cycles until death (up to 46 months)
Reported as:
Median · months
Overall Survival in ITT Population
monthsGroup A: Trastuzumab+Taxane /Capecitabine (6 Weeks)
Overall Survival in ITT PopulationNA (6.57 to 40.28)
SecondaryPart I and II: Percentage of Participants With a Best Overall Response of CR or PR in ITT Population

Best Overall response was defined according to RECIST. CR: disappearance of all target lesions and all pathological lymph nodes below 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD: At least a 20% increase in the sum of diameters of target lesions, and the sum must also demonstrate an absolute increase of at least 5 mm or persistence of non-target lesions.

Time frame:
End of first 2 Cycles (Weeks 3 and 6), every 3 Cycles for 18 weeks, then every 4 cycles until progression, unacceptable toxicity or participant decision to cease treatment up to 46 months
Reported as:
Number · percentage of participants
Part I and II: Percentage of Participants With a Best Overall Response of CR or PR in ITT Population
percentage of participantsGroup A: Trastuzumab+Taxane /Capcetabine (6 Weeks)
Part I: Responders (n=20)75.0
Part I: Non-Responders (n=20)20.0
Part I: Missing (n=20)5.0
Part II: Responders (n=9)11.1
Part II: Non-Responders (n=9)88.9
Part II: Missing (n=9)0.0
PrimaryPart II: TTP by Biomarker

TTP was calculated from first study medication in Part II to date of progression. The relationship between TTP and the following biomarker variables was investigated in each of study Part 1 and 2: p95 HER2 +ve and -ve population, IGF1R \<median and ≥median, c-MET \<median and ≥median, PTEN \<median and ≥median, HER2 \<median and ≥median, PI3K catalytic subunit WT and M, and FC gamma receptors IIIa, IIa and IIb Phenotypes FF, VF and VV, HH, HR and RR, and II, IT and TT .

Time frame:
End of first 2 Cycles (Weeks 3 and 6), every 3 cycles for 18 weeks, then every 4 cycles until progression, unacceptable toxicity or participant decision to cease treatment up to 46 months
Reported as:
Median · months
Part II: TTP by Biomarker
monthsGroup A: Trastuzumab+Taxane /Capecitabine (6 Weeks)Group B: Trastuzumab+Taxane/ Capecitabine <6 Weeks
p95 HER2 +ve (n=2,0)8.148 (NA to NA)NA (NA to NA)
p95 HER2 -ve (n=5,1)3.450 (0.854 to 8.115)13.832 (NA to NA)
IGF1R <median (n=4,0)8.115 (0.854 to 8.115)NA (NA to NA)
IGF1R ≥median (n=4,1)4.074 (1.971 to 8.148)13.832 (NA to NA)
c-MET <median (n=3,1)4.698 (3.450 to 4.698)13.832 (NA to NA)
c-MET ≥median (n=4,0)5.043 (0.854 to 8.148)NA (NA to NA)
PTEN <median (n=4,0)4.698 (1.971 to 8.115)NA (NA to NA)
PTEN ≥median (n=3,1)3.450 (0.854 to 8.148)13.832 (NA to NA)
HER2 <median (n=2,1)8.148 (NA to NA)13.832 (NA to NA)
HER2 ≥median (n=5,0)3.450 (0.854 to 8.115)NA (NA to NA)
PI3K Amino Acids WT (n=10,1)5.651 (1.971 to 8.148)13.832 (NA to NA)
PI3K Amino Acids M (n=2,0)4.485 (0.854 to 8.115)NA (NA to NA)
FC Gamma Receptor IIIa F176V FF (n=4,0)4.320 (0.854 to 8.148)NA (NA to NA)
FC Gamma Receptor IIIa F176V VF (n=2,1)NA (3.450 to NA)13.832 (NA to NA)
FC Gamma Receptor IIIa F176V VV (n=2,0)NA (NA to NA)NA (NA to NA)
FC Gamma Receptor IIa R166H HH (n=1,0)3.450 (NA to NA)NA (NA to NA)
FC Gamma Receptor IIa R166H HR (n=5,1)8.115 (0.854 to 8.148)13.832 (NA to NA)
FC Gamma Receptor IIa R166H RR (n=3,0)5.651 (2.990 to 5.651)NA (NA to NA)
FC Gamma Receptor IIb I232T II (n=7,1)5.651 (0.854 to 8.115)13.832 (NA to NA)
PrimaryPart I: Percentage of Participants With a Best Overall Response (BOR) of Complete Response (CR), Partial Response (PR), Stable Disease (SD) or Progrerssive Disease (PD) by Biomarker

BOR was defined according to the Response Evaluation Criteria In Solid Tumors (RECIST). CR: disappearance of all target lesions and all pathological lymph nodes below 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD: At least a 20% increase in the sum of diameters of target lesions, and the sum must also demonstrate an absolute increase of at least 5 mm or persistence of non-target lesions. The relationship between best response and the following biomarkers was investigated: p95 HER2 (+ve/-ve), IGF1R, c-MET, PTEN, HER2 (median/≥median), PI3K catalytic subunit (WT/M), and FC gamma receptors IIIa, IIa and IIb (phenotypes FF, VF, VV, HH, HR, RR and II, IT and TT respectively). The correlation between the biomarker variables and percentage of participants with best response were investigated using a univariate regression analysis.

Time frame:
End of first 2 Cycles (Weeks 3 and 6), every 3 cycles for 18 weeks, then every 4 cycles until progression, unacceptable toxicity or participant decision to cease treatment up to 46 weeks
Reported as:
Number · percentage of participants
Part I: Percentage of Participants With a Best Overall Response (BOR) of Complete Response (CR), Partial Response (PR), Stable Disease (SD) or Progrerssive Disease (PD) by Biomarker
percentage of participantsGroup A: Trastuzumab+Taxane /Capecitabine (6 Weeks)
p95 HER2 +ve CR (n=5)0.0
p95 HER2 +ve PR (n=5)25.0
p95 HER2 +ve SD (n=5)50.0
p95 HER2 +ve PD (n=5)25.0
p95 HER2 -ve CR (n=12)0.0
p95 HER2 -ve PR (n=12)91.7
p95 HER2 -ve SD (n=12)8.3
p95 HER2 -ve PD (n=12)0.0
IGF1R < median CR (n=9)0.0
IGF1R < median PR (n=9)62.5
IGF1R < median SD (n=9)37.5
IGF1R < median PD (n=9)0.0
IGF1R ≥median CR (n=9)0.0
IGF1R ≥median PR (n=9,0)88.9
IGF1R ≥median SD (n=9)0.0
IGF1R ≥median PD (n=9)11.1
c-MET <median CR (n=6)0.0
c-METt <median PR (n=6)83.3
c-MET <median SD (n=6)0.0
c-MET <median PD (n=6)16.7
c-MET ≥median CR (n=11)0.0
c-MET ≥median PR (n=11)70.0
c-MET ≥median SD (n=11)30.0
c-MET ≥median PD (n=11)0.0
PTEN <median CR (n=6)0.0
PTEN <median PR (n=6)83.3
PTEN <median SD (n=6)16.7
PTEN <median PD (n=6)0.0
PTEN ≥median CR (n=12)0.0
PTEN ≥median PR (n=12)72.7
PTEN ≥median SD (n=12)18.2
PTEN ≥median PD (n=12)9.1
HER2 <median CR (n=8)0.0
HER2 <median PR (n=8)75.0
HER2 <median SD (n=8)12.5
HER2 <median PD (n=8)12.5
HER2 ≥median CR (n=10)0.0
HER2 ≥median PR (n=10)77.8
HER2 ≥median SD (n=10)22.2
HER2 ≥median PD (n=10)0.0
PI3K Amino Acids WT CR (n=11)0.0
PI3K Amino Acids WT PR (n=11,0)90.0
PI3K Amino Acids WT SD (n=11)0.0
PI3K Amino Acids WT PD (n=11)10.0
PI3K Amino Acids M CR (n=7)0.0
PI3K Amino Acids M PR (n=7,0)57.1
PI3K Amino Acids M SD (n=7)42.9
PI3K Amino Acids M PD (n=7)0.0
FC Gamma Receptor IIIa F176V FF CR (n=6)16.7
FC Gamma Receptor IIIa F176V FF PR (n=6)50.0
FC Gamma Receptor IIIa F176V FF SD (n=6)16.7
FC Gamma Receptor IIIa F176V FF PD (n=6)16.7
FC Gamma Receptor IIIa F176V VF CR (n=4)0.0
FC Gamma Receptor IIIa F176V VF PR (n=4)66.7
FC Gamma Receptor IIIa F176V VF SD (n=4)33.3
FC Gamma Receptor IIIa F176V VF PD (n=4)0.0
FC Gamma Receptor IIIa F176V VV CR (n=2)0.0
FC Gamma Receptor IIIa F176V VV PR (n=2)100.0
FC Gamma Receptor IIIa F176V VV SD (n=2)0.0
FC Gamma Receptor IIIa F176V VV PD (n=2)0.0
FC Gamma Receptor IIa R166H HH CR (n=3)33.3
FC Gamma Receptor IIa R166H HH PR (n=3)66.7
FC Gamma Receptor IIa R166H HH SD (n=3)0.0
FC Gamma Receptor IIa R166H HH PD (n=3)0.0
FC Gamma Receptor IIa R166H HR CR (n=5)0.0
FC Gamma Receptor IIa R166H HR PR (n=5)25.0
FC Gamma Receptor IIa R166H HR SD (n=5)50.0
FC Gamma Receptor IIa R166H HR PD (n=5)25.0
FC Gamma Receptor IIa R166H RR CR (n=5)0.0
FC Gamma Receptor IIa R166H RR PR (n=5)80.0
FC Gamma Receptor IIa R166H SD RR (n=5)20.0
FC Gamma Receptor IIa R166H RR PD (n=5)0.0
FC Gamma Receptor IIb I232T II CR (n=8)12.5
FC Gamma Receptor IIb I232T II PR (n=8)50.0
FC Gamma Receptor IIb I232T II SD (n=8)37.5
FC Gamma Receptor IIb I232T II PD (n=8)0.0
FC Gamma Receptor IIb I232T IT CR (n=1)0.0
FC Gamma Receptor IIb I232T IT PR (n=1)100.0
FC Gamma Receptor IIb I232T IT SD (n=1)0.0
FC Gamma Receptor IIb I232T IT PD (n=1)0.0
Statistical analysis
  • Group A: Trastuzumab+Taxane /Capecitabine (6 Weeks) · Odds ratio (or): 0.030 · 95% CI 0.001 to 0.641
  • Group A: Trastuzumab+Taxane /Capecitabine (6 Weeks) · Odds ratio (or): 0.208 · 95% CI 0.017 to 2.600
  • Group A: Trastuzumab+Taxane /Capecitabine (6 Weeks) · Odds ratio (or): 2.143 · 95% CI 0.169 to 27.103
  • Group A: Trastuzumab+Taxane /Capecitabine (6 Weeks) · Odds ratio (or): 1.875 · 95% CI 0.150 to 23.396
  • Group A: Trastuzumab+Taxane /Capecitabine (6 Weeks) · Odds ratio (or): 0.857 · 95% CI 0.091 to 8.075
  • Group A: Trastuzumab+Taxane /Capecitabine (6 Weeks) · Odds ratio (or): 0.148 · 95% CI 0.012 to 1.900
  • Group A: Trastuzumab+Taxane /Capecitabine (6 Weeks) · Odds ratio (or): 1.000 · 95% CI 0.053 to 18.915
  • Group A: Trastuzumab+Taxane /Capecitabine (6 Weeks) · Odds ratio (or): 0.083 · 95% CI 0.004 to 1.945
PrimaryPart II: Percentage of Participants With a Best Overall Response of CR, PR, SD or PD by Biomarker

Best Overall response was defined according to RECIST. CR: disappearance of all target lesions and all pathological lymph nodes below 10 mm.PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD: At least a 20% increase in the sum of diameters of target lesions, and the sum must also demonstrate an absolute increase of at least 5 mm or persistence of non-target lesions. The relationship between best response and the following biomarkers was investigated: p95 HER2 (+ve/-ve), IGF1R, c-MET, PTEN, HER2 (\<median/≥median) , PI3K catalytic subunit (WT/M), and FC gamma receptors IIIa, IIa and IIb (phenotypes FF, VF, VV, HH, HR, RR and II, IT and TT respectively). The correlation between the biomarker variables and percentage of participants with best response were investigated using a univariate regression analysis.

Time frame:
End of first 2 Cycles (Weeks 3 and 6), every 3 cycles for 18 weeks, then every 4 cycles until progression, unacceptable toxicity or participant decision to cease treatment up to 46 months
Reported as:
Number · percentage of participants
Part II: Percentage of Participants With a Best Overall Response of CR, PR, SD or PD by Biomarker
percentage of participantsGroup A: Trastuzumab+Taxane /Capecitabine (6 Weeks)
p95 HER2 +ve CR (n=2)0.0
p95 HER2 +ve PR (n=2)0.0
p95 HER2 +ve SD (n=2)100.0
p95 HER2 +ve PD (n=2)0.0
p95 HER2 -ve CR (n=4)0.0
p95 HER2 -ve PR (n=4)0.0
p95 HER2 -ve SD (n=4)50.0
p95 HER2 -ve PD (n=4)50.0
IGF1R <median CR (n=3)0.0
IGF1R <median PR (n=3)0.0
IGF1R <median SD (n=3)66.7
IGF1R <median PD (n=3)33.3
IGF1R ≥median CR (n=3)0.0
IGF1R ≥median PR (n=3)0.0
IGF1R ≥median SD (n=3)66.7
IGF1R ≥median PD (n=3)33.3
c-MET <median CR (n=2)0.0
c-MET <median PR (n=2)0.0
c-MET <median SD (n=2)100.0
c-MET <median PD (n=2)0.0
c-MET ≥median CR (n=4)0.0
c-MET ≥median PR (n=4)0.0
c-MET ≥median SD (n=4)50.0
c-MET ≥median PD (n=4)50.0
PTEN <median CR (n=4)0.0
PTEN <median PR (n=4)0.0
PTEN <median SD (n=4)75.0
PTEN <median PD (n=4)25.0
PTEN ≥median CR (n=2)0.0
PTEN ≥median PR (n=2)0.0
PTEN ≥median SD (n=2)50.0
PTEN ≥median PD (n=2)50.0
HER2 <median CR (n=2)0.0
HER2 <median PR (n=2)0.0
HER2 <median SD (n=2)100.0
HER2 <median PD (n=2)0.0
HER2 ≥median CR (n=4)0.0
HER2 ≥median PR (n=4)0.0
HER2 ≥median SD (n=4)50.0
HER2 ≥median PD (n=4)50.0
PI3K Amino Acids WT CR (n=7)0.0
PI3K Amino Acids WT PR (n=7)14.3
PI3K Amino Acids WT SD (n=7)71.4
PI3K Amino Acids WT PD (n=7)14.3
PI3K Amino Acids M CR (n=2)0.0
PI3K Amino Acids M PR (n=2)0.0
PI3K Amino Acids M SD (n=2)50.0
PI3K Amino Acids M PD (n=2)50.0
FC Gamma Receptor IIIa F176V FF CR (n=3)0.0
FC Gamma Receptor IIIa F176V FF PR (n=3)0.0
FC Gamma Receptor IIIa F176V FF SD (n=3)66.7
FC Gamma Receptor IIIa F176V FF PD (n=3)33.3
FC Gamma Receptor IIIa F176V VF CR (n=1)0.0
FC Gamma Receptor IIIa F176V VF PR (n=1)0.0
FC Gamma Receptor IIIa F176V VF SD (n=1)100.0
FC Gamma Receptor IIIa F176V VF PD (n=1)0.0
FC Gamma Receptor IIIa F176V VV CR (n=1)0.0
FC Gamma Receptor IIIa F176V VV PR (n=1)100.0
FC Gamma Receptor IIIa F176V VV SD (n=1)0.0
FC Gamma Receptor IIIa F176V VV PD (n=1)0.0
FC Gamma Receptor IIa R166H HH CR (n=0)NA
FC Gamma Receptor IIa R166H HH PR (n=0)NA
FC Gamma Receptor IIa R166H HH SD (n=0)NA
FC Gamma Receptor IIa R166H HH PD (n=0)NA
FC Gamma Receptor IIa R166H HR CR (n=5)0.0
FC Gamma Receptor IIa R166H HR PR (n=4)25.0
FC Gamma Receptor IIa R166H HR SD (n=4)50.0
FC Gamma Receptor IIa R166H HR PD (n=4)25.0
FC Gamma Receptor IIa R166H RR CR (n=4)0.0
FC Gamma Receptor IIa R166H RR PR (n=2)0.0
FC Gamma Receptor IIa R166H RR SD (n=2)100.0
FC Gamma Receptor IIa R166H RR PD (n=2)0.0
FC Gamma Receptor IIb I232T II CR (n=4)0.0
FC Gamma Receptor IIb I232T II PR (n=4)0.0
FC Gamma Receptor IIb I232T II SD (n=4)75.0
FC Gamma Receptor IIb I232T II PD (n=4)25.0
FC Gamma Receptor IIb I232T IT CR (N=0)NA
FC Gamma Receptor IIb I232T IT PR (n=0)NA
FC Gamma Receptor IIb I232T IT SD (n=0)NA
FC Gamma Receptor IIb I232T IT PD (n=0)NA
FC Gamma Receptor IIb I232T TT CR (n=4)0.0
FC Gamma Receptor IIb I232T TT PR (n=4)0.0
FC Gamma Receptor IIb I232T TT SD (n=4)75.0
FC Gamma Receptor IIb I232T TT PD (n=4)25.0
SecondaryPart I and II: Percentage of Participants With a Response by Best Overall Response by CR, PR, SD or PD in ITT Population

Best Overall response was defined according to RECIST. CR: disappearance of all target lesions and all pathological lymph nodes below 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD: At least a 20% increase in the sum of diameters of target lesions, and the sum must also demonstrate an absolute increase of at least 5 mm or persistence of non-target lesions.

Time frame:
End of first 2 Cycles (Weeks 3 and 6), every 3 cycles for 18 weeks, then every 4 cycles until progression, unacceptable toxicity or participant decision to cease treatment up to 46 months
Reported as:
Number · percentage of participants
Part I and II: Percentage of Participants With a Response by Best Overall Response by CR, PR, SD or PD in ITT Population
percentage of participantsGroup A: Trastuzumab+Taxane /Capecitabine (6 Weeks)
Part I: CR (n=20)5.0
Part I: PR (n=20)70.0
Part I: SD (n=20)15.0
Part I: PD (n=20)5.0
Part I: Missing (n=20)5.0
Part II: CR (n=9)0.0
Part II: PR (n=9)11.1
Part II: SD (n=9)66.7
Part II: PD (n=9)22.2
Part II: Missing (n=9)0.0

Adverse events

Collected over From the date of Screening until 4 weeks after the last visit of the participant. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Participants—9/33 (27.3%)33/33 (100%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventAll Participants
PyrexiaGeneral disorders2/33
Chest painGeneral disorders1/33
Medical device complicationGeneral disorders1/33
CellulitisInfections and infestations1/33
SepsisInfections and infestations1/33
Febrile neutropeniaBlood and lymphatic system disorders1/33
Cardiac failureCardiac disorders1/33
Hip fractureInjury, poisoning and procedural complications1/33
Back painMusculoskeletal and connective tissue disorders1/33
MenorrhagiaReproductive system and breast disorders1/33
Most frequent other events
Showing 10 of 116
Most frequent other events
EventAll Participants
Nail disorderSkin and subcutaneous tissue disorders23/33
RashSkin and subcutaneous tissue disorders22/33
FatigueGeneral disorders21/33
DiarrhoeaGastrointestinal disorders20/33
NauseaGastrointestinal disorders20/33
AlopeciaSkin and subcutaneous tissue disorders16/33
Peripheral sensory neuropathyNervous system disorders16/33
HeadacheNervous system disorders15/33
VomitingGastrointestinal disorders13/33
ArthralgiaMusculoskeletal and connective tissue disorders13/33

Baseline characteristics

Intent-to-treat (ITT) population: All registered participants were included in the ITT population.

Age, Continuous
Age, Continuous(years)Group A: Trastuzumab+Taxane /Capecitabine (6 Weeks)Group B: Trastuzumab+Taxane/ Capecitabine <6 WeeksNo GroupTotal
Mean55.5 ± 11.7337.0 ± NA85.0 ± NA55.9 ± 12.91
Sex: Female, Male
Sex: Female, Male(Participants)Group A: Trastuzumab+Taxane /Capecitabine (6 Weeks)Group B: Trastuzumab+Taxane/ Capecitabine <6 WeeksNo GroupTotal
Female311133
Male0000
08

Study locations

13 sites
  • Royal Prince Alfred Hospital; Medical Oncology
    Camperdown, New South Wales 2050, Australia
  • Royal North Shore Hospital; Oncology
    St. Leonards, New South Wales 2065, Australia
  • Eastern Health Breast Cancer Research
    East Ringwood, Victoria 3135, Australia
  • Border Medical Oncology; Murray Valley Private Hospital
    Wodonga, Victoria 3690, Australia
  • Mount Medical Center
    Perth, Western Australia 6000, Australia
  • Royal Perth Hospital; Department of Medical Oncology
    Perth, Western Australia 6000, Australia
  • Hospital Universitario Marques de Valdecilla; Servicio de Oncologia
    Santander, Cantabria 39008, Spain
  • Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia
    Valencia, 46010, Spain
  • Karolinska Hospital; Oncology - Radiumhemmet
    Stockholm, 17176, Sweden
  • Akademiska sjukhuset, Onkologkliniken
    Uppsala, 75185, Sweden
  • Hull Royal Infirmary
    Hull, HU3 2JZ, United Kingdom
  • Christie Hospital; Breast Cancer Research Office
    Manchester, M20 4QL, United Kingdom
  • Nottingham City Hospital; Oncology
    Nottingham, NG5 1PB, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2009 to primary completion in Feb 2013, 42 months.

Results were first posted in Oct 2015, 2 years 7 months after primary completion.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 42 months is above that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2009
First posted
Apr 22, 2009
StartActual
Aug 13, 2009
Primary completionActual
Feb 18, 2013
CompletionActual
Feb 18, 2013
Results first posted
Oct 5, 2015
Last update
Mar 29, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00885755
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Apr 22, 2009
Start date
Aug 13, 2009
Primary completion
Feb 18, 2013
Completion
Feb 18, 2013
Results posted
Oct 5, 2015
Last update
Mar 29, 2018

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Capecitabine · Trastuzumab

Start the discussion